A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years

Exclusion Criteria

• •Known hypersensitivity to a previous dose of Influenza Virus Vaccine or allergy to eggs or any components of the study vaccines.
• •Clinical signs of significant active infection or an elevated oral temperature at study entry.
• •A clinically significant medical or psychiatric condition.
• •A history of seizures or febrile convulsions or Guillain-Barré syndrome.
• •Vaccination with a seasonal or experimental influenza virus vaccine in the 6 months preceding study entry.
• •Vaccination with a licensed vaccine within 14 days preceding study entry, or planning to be vaccinated with another licensed vaccine before the study exit evaluation.
• •Currently receiving systemic glucocorticoid therapy (excluding intra-articular, topical or inhaled preparations) or have received such therapy within the 3 months preceding study entry.
• •Currently receiving immunoglobulins and/or any blood products or have received such treatment within the 3 months preceding the administration of the study vaccine.
• •Currently receiving treatment with warfarin or other anticoagulants.